EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients: prospective feasibility and imaging response

Piotr Sobolewski iD, Mateusz Koper, Michal Poltorak, Pawel Banatkiewicz, Malgorzata Kolos, Lukasz Poltorak, Maciej Szwast, Irena Walecka

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Piotr Sobolewski und 7 weiteren Autor:innen. Beteiligte Einrichtung: The National Medical Institute of the Ministry of the Interior and Administration, Woloska 137, 02-507 Warsaw, Poland. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Brachytherapy, Printing, Three-Dimensional, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Basal cell carcinoma (BCC) is common in older adults, many of whom are poor surgical candidates, especially for curved and cosmetically sensitive facial sites. High-dose-rate (HDR) surface brachytherapy is effective, but standard flat applicators may fit poorly and increase dose heterogeneity. Patient-specific 3D-printed applicators could improve conformity, yet geriatric BCC data are limited.

Objective

To assess the feasibility and 12-month outcomes of personalized 3D-printed HDR surface brachytherapy in geriatric patients with BCC.

Methods

In this prospective single-arm study, 15 patients aged ≥65 years with histologically confirmed BCC (predominantly facial) who were unsuitable for surgery received HDR surface brachytherapy using custom 3D-printed applicators. Treatment delivered 51 Gy in 17 fractions with CT-based planning. Repeat CT imaging evaluated applicator fit/reproducibility and target coverage. Acute skin toxicity was graded by RTOG. At 12 months, response was assessed clinically and dermoscopically; cosmesis and quality of life (Dermatology Life Quality Index [DLQI]) were recorded.

Results

All patients completed treatment. Positioning was highly reproducible (mean setup error <1 mm) with >90% target dose coverage. At 12 months, all lesions achieved complete remission, with no local recurrence on dermoscopy. Acute reactions were mostly mild (73% grade 1), with 13% grade 2 and 13% grade 3; no grade 4 toxicity or serious adverse events occurred. Cosmesis was favorable, and DLQI improved (mean, 10.5 pre-treatment vs 2.9 at 1 year; P < .01).

Conclusions

Personalized 3D-printed HDR surface brachytherapy appears feasible and well tolerated in this small, single-center cohort of older patients with BCC, with favorable 1-year local control and quality-of-life improvement when surgery is contraindicated. However, the limited sample size and single-center design represent limitation, and the observed benefit should be regarded as suggestive rather than definitive.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaBrachytherapyPrinting, Three-DimensionalSkin NeoplasmsHumansAgedFemaleMaleAged, 80 and overProspective StudiesFeasibility StudiesQuality of Life

Stichwörter der Autor:innen

3D-printed applicatorbasal cell carcinomadermoscopygeriatric patientshigh-dose brachytherapy

Autor:innen und Institutionen

  • The National Medical Institute of the Ministry of the Interior and Administration, Woloska 137, 02-507 Warsaw, Poland.
  • Chair and Clinic of Dermatology and Pediatric Dermatology, Centre of Postgraduate Medical Education, 02-507Warsaw, Poland.
  • Electrochemistry at Soft Interfaces Team, Department of Inorganic and Analytical Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, 91-403 Lodz, Poland.
  • Department of Chemical and Process Engineering, Warsaw University of Technology, Warynskiego 1, 00-645 Warsaw, Poland.

ORCID-Profile: Piotr Sobolewski

Zitieren

APA

Sobolewski, P., Koper, M., Poltorak, M., Banatkiewicz, P., Kolos, M., Poltorak, L., Szwast, M., & Walecka, I. (2026). Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients: prospective feasibility and imaging response. The Oncologist. https://doi.org/10.1093/oncolo/oyag206

Vancouver

Sobolewski P, Koper M, Poltorak M, Banatkiewicz P, Kolos M, Poltorak L, et al. Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients: prospective feasibility and imaging response. The Oncologist. 2026. doi:10.1093/oncolo/oyag206

BibTeX
@article{Sobolewski2026,
  author = {Sobolewski, Piotr and Koper, Mateusz and Poltorak, Michal and Banatkiewicz, Pawel and Kolos, Malgorzata and Poltorak, Lukasz and Szwast, Maciej and Walecka, Irena},
  title = {Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients: prospective feasibility and imaging response},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag206}
}
Kostenlos starten →